Please login to the form below

Not currently logged in
Email:
Password:

Johan Heylen leaves GSK for Ablynx

He joins Nanobody specialist as chief commercial officer

edit-Johan-Heylen_Chief-Commercial-Officer_AblynxAblynx has named former GlaxoSmithKline (GSK) executive Johan Heylen as chief commercial officer.

Heylen spent 17 years at GSK, serving most recently as executive director, global commercial lead for its cancer immunotherapeutics division.

In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.

Heylen now heads commercial operations at Ablynx, growing biopharma specialising in the development of Nanobodies, tiny fragments of antibodies with therapeutic potential.

He said: "Ablynx has an extraordinary pipeline of products based on its unique Nanobody discovery platform, validated by an impressive list of partners.

“I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics."

Heylen also has experience at Servier and Wyeth having started his career in healthcare as a pharmacist.

20th November 2014

Share

Subscribe to our email news alerts

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...